The biotechnology and applications of antibody engineering

Ralph Rapley

doi:10.1007/bf02789110

journal article Apr 01, 1995

The biotechnology and applications of antibody engineering

Ralph Rapley

Molecular Biotechnology Vol. 3 No. 2 pp. 139-154 · Springer Science and Business Media LLC

View at Publisher Save 10.1007/bf02789110

Topics

No keywords indexed for this article. Browse by subject →

References

88

[1]

Horibata, K. and Harris, A.W. (1970) Mouse myelomas and lymphomas in culture.Exp. Cell Res. 60, 61–66. 10.1016/0014-4827(70)90489-1

[2]

Kohler, G. and Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of predetermined specificity.Nature 256, 495–497. 10.1038/256495a0

[3]

Borrebaeck, C. A. K., Danielsson, L., Ohlin, M., Carlsson, J., and Carlsson, R. (1990) The use ofin vitro immunization, cloning of variable regions, and SCID mice for the production of human monoclonal antibodies, inTherapeutic Monoclonal Antibodies (Borrebaeck, C. A. K. and Larrick, J. W., eds.), Stockton, New York, pp. 1–17. 10.1007/978-1-349-11894-6

[4]

Waldmann, T. A. (1991) Monoclonal antibodies in diagnosis and therapy.Science 252, 1657–1662. 10.1126/science.2047874

[5]

Banchereau, J., DePaoli, P., Valle, A., Garcia, E., and Rousset, F. (1991) Long term human B cell lines dependent on interleukin 4 and anti CD40.Science 251, 70. 10.1126/science.1702555

[6]

Bator, J. M. and Reading, C. L. (1990) Antibody mediated cancer diagnosis and therapy, inTherapeutic Monoclonal Antibodies (Borrebaeck, C. and Larrick, J., eds.), Stockton, New York, pp. 35–56. 10.1007/978-1-349-11894-6_3

[7]

Fanger, M. W. and Guyre, P. M. (1991) Bispecific antibodies for targeted cellular cytotoxicity.Trends Biotech. 9, 375–381. 10.1016/0167-7799(91)90129-6

[8]

Clark, M., Gilliland, L., and Waldmann, H. (1988) Hybrid antibodies for therapy, inMonoclonal Antibody Therapy (Waldmann, H., ed.), Karger, Basel, pp. 31–49. 10.1159/000416373

[9]

Lefranc, G. and Lefranc, M. P. (1991) Antibody engineering and perspectives in therapy.Biochemie 72, 639–649. 10.1016/0300-9084(90)90046-j

[10]

Blakey, D. C., Wawrzynczak, E. J., Wallace, P. M., and Thorpe, P. E. (1988) Antibody toxin conjugates: a perspective, inMonoclonal Antibody Therapy (Waldmann, H., ed.), Karger, Basel, pp. 50–89.

[11]

Manevich, E. M., Tonevitsky, A. G., and Bergelson, L. D. (1986) The binding of B chain of ricin to Burkitts lymphoma cells.FEBS Lett. 194, 313–318. 10.1016/0014-5793(86)80108-9

[12]

Laurent, G., Kuhlein, E., Casellas, P., Canat, X., et al. (1986) Determination of the sensitivity of fresh leukemia cells to immunotoxins.Cancer Res. 46, 2289–2294.

[13]

Youle, R. J., Newton, G., Wu, Y. N., Gadina, M., and Rybak, S. M (1993) Cytotoxic ribonucleases and chimeras in cancer therapy.Crit. Rev. Ther. Drug Carrier Syst 10(1), 1–28.

[14]

Sandlie, I. and Michaelsen, T. E. (1991) Engineering monoclonal antibodies to determine the structural requirements for complement activation and complement mediated lysis.Mol. Immunol. 28(12), 1361–1366. 10.1016/0161-5890(91)90038-l

[15]

Mendelsohn, J. (1988) Growth factor receptors as targets for antitumor therapy with monoclonal antibodies, inMonoclonal Antibody Therapy (Waldmann, H., ed.), Karger, Basel, pp. 147–160. 10.1159/000416378

[16]

Winter, G. and Harris, W. J. (1993) Humanized antibodies (1993)Immunol. Today 14(6), 243–246.

[17]

Morrison, S. L., Canfield, S., Porter, S., Tan, L. K., Tao, M., and Wims, L. A. (1988) Production and characterization of genetically engineered antibody molecules.Clin. Chem. 34(9), 1668–1672. 10.1093/clinchem/34.9.1668

[18]

Jolliffe, L. K. (1993) Humanized antibodies: enhancing therapeutic utility through antibody engineering.Int Rev Immunol. 10(2), 241–250. 10.3109/08830189309061699

[19]

LoBuglio, A. F., Wheeler, R. H., Trang, J., Haynes, A., et al. (1989) Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.Proc. Natl. Acad. Sci. USA 86, 4220–4224. 10.1073/pnas.86.11.4220

[20]

Liu, A. Y., Robinson, R. R., Hellstrom, K. E., Murrey, E. D., et al. (1987) Chimeric mouse-human IgGl antibody that can mediate lysis of cancer cells.Proc. Natl. Acad. Sci. USA 84, 3439–3443. 10.1073/pnas.84.10.3439

[21]

Bright, S., Adair, J., and Secher, D. (1991) From laboratory to clinic: the development of an immunological reagent.Immunol. Today 12(4), 130–136. 10.1016/0167-5699(91)90097-d

[22]

Shagan, B. G., Dorai, H., Saltzgaber-Muller, J., Toneguzzo, F., Guindon, C. A., et al. (1986) A genetically engineered murine/human chimeric antibody retains specificity for human tumor associated antigen.J. Immunol. 137, 1066–1072. 10.4049/jimmunol.137.3.1066

[23]

Bruggemann, M., Williams, G. T., Bindon, C. I., Teale, C., Clark, M. R., et al. (1987) Comparison of effector functions of human immunoglobulins using a matched set of chimeric antibodies.J. Exp. Med. 166, 1351–1355. 10.1084/jem.166.5.1351

[24]

Bruggemann, M., Winter, G., Waldmann, H., and Neuberger, M. S. (1989) The immunogenicity of chimeric antibodies.J. Exp. Med. 170, 2153–2159. 10.1084/jem.170.6.2153

[25]

Verhoeyen, M., Milstein, C., and Winter, G. (1988) Reshaping human antibodies: Grafting an anti lysozyme activity.Science 239, 1534–1538. 10.1126/science.2451287

[26]

Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., and Winter G. (1986) Replacing the complementarity determining region in a human antibody with those from a mouse.Nature 321, 522–525. 10.1038/321522a0

[27]

Reichmann, L., Clark, M., Waldmann, H., and Winter, G. (1988) Reshaping human antibodies for therapy.Nature 332, 323–327. 10.1038/332323a0

[28]

Tempest, P. R., Bremmer, P., Lambert, M., Taylor, G., et al. (1991) Reshaping a human monoclonal antibody to inhibit respiratory syncytical virus infectionin vivo.Bio/Technology 9, 266–271. 10.1038/nbt0391-266

[29]

Colnaghi, M. I., Menard, S., and Canevari, S. (1993) Evolution of the therapeutic use of new monoclonal antibodies.Curr. Opin. Oncol. 5(6), 1035–1042. 10.1097/00001622-199311000-00015

[30]

Winter, G. and Milstein, C. (1991) Man-made antibodies.Nature 349, 293–299. 10.1038/349293a0

[31]

Cunningham, C. and Harris, W. J. (1992) Antibody engineering-how to be human.Trends Biotechnol. 10, 112–118. 10.1016/0167-7799(92)90191-w

[32]

Roberts, S., Cheetham, J., and Rees, A. R. (1987) Generation of an antibody with enhanced affinity and specificity for its antigen by protein engineering.Nature 328, 731–733. 10.1038/328731a0

[33]

Kussie, P. H., Parhami-Seren, B., Wysocki, L. J., and Margolies, M. N. (1994) A single engineered amino acid substitution changes antibody fine specificity.J. Immunol. 152(1), 146–152. 10.4049/jimmunol.152.1.146

[34]

Xiang, J., Chen, Z., Delbaere, L. T., and Liu, E. (1993) Differences in antigen binding affinity caused by a single amino acid substitution in the variable region of the heavy chain.Immunol. Cell. Biol. 71(4), 239–247. 10.1038/icb.1993.28

[35]

Queen, C., Schneider, W. P., Selick, H. E., Payne, P.W., et al. (1989) A humanized antibody that binds to the interleukin 2 receptor.Proc. Natl. Acad. Sci. USA 86, 1029–1034. 10.1073/pnas.86.24.10029

[36]

Co, M. S. and Queen, C. (1991) Humanized antibodies for therapy.Nature 351, 501–505. 10.1038/351501a0

[37]

Iverson, B. L., Iverson, S. A., Roberts, V. A., Getzoff, E. D., Tainer, J. A., Benkovic, S. J., and Lerner, R. A. (1990) MetalloantibodiesScience 249, 659–662. 10.1126/science.2116666

[38]

Getzoff, E. D., Tainer, J. A., and Lerner, R. A. (1988) The chemistry and mechanism of antibody binding to protein antigens.Adv. Immunol. 43, 1. 10.1016/s0065-2776(08)60363-6

[39]

Roberts, V., Iverson, B., Benkovic, S., Lerner, R. A., Getzoff, E. D., and Tainer, J. A. (1990) Antibody remodelling: A general solution to the design of a metal coordination site in an antibody binding pocket.Proc. Natl. Acad. Sci. USA 87, 6654–6658. 10.1073/pnas.87.17.6654

[40]

Balint, R. F. and Larrick, J. W. (1993) Antibody engineering by parsimonious mutagenesis.Gene 137(1), 109–118. 10.1016/0378-1119(93)90258-5

[41]

Rodwell, J. D. (1989) Engineering monoclonal antibodies.Nature 342, 99–101. 10.1038/342099a0

[42]

Wetzel, R. (1988) Active immunoglobulin fragments synthesised inE. coli-from Fab to scantibodies.Protein Eng. 2(3), 169–175. 10.1093/protein/2.3.169

[43]

Skerra, A. and Pluckthun, A. (1988) Assembly of a functional immunoglobulin Fv fragment inE. coli. Science 240, 1038–1040. 10.1126/science.3285470

[44]

Pluckthun, A. (1992) Mono and bivalent antibody fragments produced inE. coli: engineering, folding and antigen binding.Immunol. Rev. 130, 151–188. 10.1111/j.1600-065x.1992.tb01525.x

[45]

Skerra, A., Pfitzinger, I., and Pluckthun, A. (1990) The functional expression of antibody Fv fragments inE. coli: improved vectors and a generally applicable purification strategy.Bio/Technology 9, 273–278. 10.1038/nbt0391-273

[46]

Pluckthun, A. (1991) Antibody engineering: Advances from the use of Escherichia coli expression systems.Bio/Technology 9, 545–551. 10.1038/nbt0691-545

[47]

Freudl, R. (1989) Insertion of peptides into cell-exposed-areas ofE. coli. OmpA does not interfere with export and membrane assembly.Gene 82, 229–234. 10.1016/0378-1119(89)90048-6

[48]

Haseman, C. A. and Capra, J. D. (1990) High level production of a functional immunoglobulin heterodimer in a baculovirus expression system.Proc. Natl. Acad. Sci. USA 87, 3942–3946. 10.1073/pnas.87.10.3942

[49]

Hiatt, A. C. (1991) Monoclonal antibodies, hybridoma technology and heterologous production systems.Curr. Opin. Immunol. 3, 229–235. 10.1016/0952-7915(91)90056-7

[50]

Skerra, A., Dreher, M. L., and Winter, G. (1991) Filter screening of antibody Fab fragments secreted from individual bacterial colonies: specific detection of antigen binding with a two membrane system.Anal. Biochem. 196, 151–156. 10.1016/0003-2697(91)90131-c

Showing 50 of 88 references

Metrics

25

Citations

88

References

Details

Published: Apr 01, 1995
Vol/Issue: 3(2)
Pages: 139-154
License: View

Authors

R

Ralph Rapley

Cite This Article

Ralph Rapley (1995). The biotechnology and applications of antibody engineering. Molecular Biotechnology, 3(2), 139-154. https://doi.org/10.1007/bf02789110

The biotechnology and applications of antibody engineering

You May Also Like